Gregg A. Olsen - Concepedia

Author

Gregg A. Olsen

Duke Medical Center

Also Known As

G A Olsen, G Olsen, G. A. Olsen, Gregg A. Olsen, Gregg Olsen, Olsen, Gregg Arden

Publications

945

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center University of Utah Providence Saint Joseph Medical Center Seagen (United States)Willamette Valley Cancer Institute and Research Center

About

Gregg A. Olsen is an author at Duke Medical Center specializing in medicine, health sciences, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	526
2	Health Sciences	3	3	502
3	Immunology	2	2	97
4	Allergy	1	1	73
5	Medical Laboratory Science	1	1	45

Gregg A. Olsen

Publications

917

Citations

H-Index

Page 1

	Year	Citations
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. W. P. Peters, E.J. Shpall, R B Jones, Journal of Clinical Oncology Metastatic Breast CancerBreast OncologyMedian DurationMedicinePharmacology	1988	384
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older Andres Forero‐Torres, Beata Holkova, Jerome H. Goldschmidt, Blood	2015	137
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL Jonathan W. Friedberg, Andres Forero‐Torres, Rodolfo Bordoni, Blood	2017	88
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. W. P. Peters, W. David Henner, L B Grochow, PubMed Solid TumorsImmunologyPathologyPharmacotherapyPharmacologic Effects	1987	73
Fine-needle aspiration biopsy of the mediastinum James Linder, Gregg A. Olsen, William W. Johnston The American Journal of Medicine Gross AnatomyMedical ImagingMedicineSurgical PathologyHistopathology	1986	45
ALTERED IMMUNOLOGIC RECONSTITUTION AFTER STANDARD-DOSE CHEMOTHERAPY OR HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW SUPPORT Gregg A. Olsen, Jon P. Gockerman, Robert C. Bast, Transplantation	1988	43
Mitoxantrone in the treatment of relapsed and refractory acute leukemia. J O Moore, Gregg A. Olsen PubMed	1984	35
Effect of Treatment with Exogenous Interferon, Polyriboinosinic-Polyribocytidylic Acid, or Polyriboinosinic-Polyribocytidylic Acid-Poly-L-Lysine Complex on Herpesvirus hominis Infections in Mice Gregg A. Olsen, Earl R. Kern, James C. Overall, The Journal of Infectious Diseases	1978	28
Effect of Treatment with Exogenous Interferon, Polyinosinic Acid-Polycytidylic Acid, or Polyinosinic Acid-Polycytidylic Acid-Poly- <scp>l</scp> -Lysine Complex on Encephalomyocarditis Virus Infections in Mice Gregg A. Olsen, Earl R. Kern, Lowell A. Glasgow, Antimicrobial Agents and Chemotherapy	1976	25
Treatment of a Murine Cytomegalovirus Infection with Exogenous Interferon, Polyinosinic-Polycytidylic Acid, and Polyinosinic-Polycytidylic Acid–Poly- <scp>l</scp> -Lysine Complex Earl R. Kern, Gregg A. Olsen, James C. Overall, Antimicrobial Agents and Chemotherapy Cytomegalovirus InfectionViral PersistenceNeurovirologyImmunologyExogenous Interferon	1978	24

Page 1